Our Science

Our Science

Our Strategy

A diversified clinical-stage pipeline shaped by:

  • Clear understanding of cancer pathways (systems biology)
  • Treatments designed with pharmacological properties to match disease need
  • Biomarker-driven clinical strategies with clear clinical rationale

First-in-Class Solutions

Merrimack has a proven history of successfully discovering and developing novel therapeutics that have helped to shape new treatment strategies for patients. That includes the successful development and approval for ONIVYDE®1 (irinotecan liposome injection) to treat patients with advanced pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy.

Today, that journey continues. Merrimack is developing a new generation of first-in-class solutions for cancer through a focused pipeline of precise, targeted therapies. A cornerstone of our development strategy is to establish efficacy and value through clinical studies in biomarker-enriched patient populations.

1ONIVYDE® was acquired by Ipsen S.A. in April 2017.

Clinical Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
MM-121
First-in-class mAb targeting HER3
Description:
HRG+, non-small cell lung cancer (NSCLC) adenocarcinoma
Study Name:
SHERLOC study
Status:
Enrolling, Phase 2 randomized data in 2H 2018
Phase 2
Description:
HRG+, HR+, HER2- metastatic breast cancer
Study Name:
SHERBOC study
Status:
Initiating in 2017
Phase 2
MM-141
Bispecific antibody targeting IGF1-R and HER3
Description:
IGF+ front-line metastatic pancreatic cancer
Study Name:
CARRIE study
Status:
Enrollment complete, Phase 2 randomized data in 1H 2018
Phase 2
MM-310
Novel antibody directed nanotherapeutic (ADN) targeting EphA2 receptor
Description:
Solid tumors
Status:
Enrolling, Phase 1 data in 2H 2018
Phase 1

Learn more about our ongoing studies at clinicaltrials.gov.

Focused Strategy

In addition to our existing focused clinical pipeline, we are taking a systematic approach to our preclinical development work.

These and other innovative programs utilizing our biomarker-driven approach will provide future opportunities to enter the clinic to help patients in need.

Preclinical Pipeline

Target
discovery
Target
validation
Lead
discovery
Lead
optimization
Pharmacologic
profiling
Ind
filing
MM-161
Monoclonal antibody targeting FGFR IIIc-Isoforms
Pharmacologic profiling
ATRI
Nanoliposome targeting ATR
Pharmacologic profiling
TRAIL
Ligand fusion targeting Death Receptor 4 and Death Receptor 5
Lead optimization
BCL2/BCLXL
Nanoliposome targeting BCL2/BCLXL
Lead optimization
Immuno-oncology
Undisclosed
Lead discovery
STIMULI™
Multi-specific TNF receptor agonists targeting co-expression on the desired cell type
Target validation

Commitment to Collaboration

Discovering and developing breakthrough cancer solutions takes a collaborative effort.
Learn more about how to work with us here.

Click here for our policy on Access to Investigational Products Outside of a Clinical Trial.